Grace Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Grace Therapeutics, Inc. (GRCE) reported Deferred Income Tax Expense (Benefit) of -$1.70 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-06-18
- Grace Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$1.70M.
- Grace Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $0.00.
- Grace Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $0.00.
- Grace Therapeutics, Inc. deferred income tax expense (benefit) for the quarter ending 2025-06-30 was $0.00.
- Grace Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2026 was -$1.70M.
- Grace Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2025 was -$3.20M.
- Grace Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$1.83M.
- Grace Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$9.54M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | -$1.70M derived: sum of 2 quarters · filed 2026-06-18 | -$1.70M derived: sum of 3 quarters · filed 2026-06-18 | -$1.70M 10-K · filed 2026-06-18 |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $0.00 10-Q · filed 2026-02-12 | -$1.02M derived: sum of 4 quarters · filed 2026-06-18 |
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | -$1.02M derived: sum of 3 quarters · filed 2026-06-18 | -$1.63M derived: sum of 4 quarters · filed 2026-06-18 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | -$1.02M derived: sum of 2 quarters · filed 2026-06-18 | -$1.63M derived: sum of 3 quarters · filed 2026-06-18 | -$2.48M derived: sum of 4 quarters · filed 2026-06-18 |
| 2025-03-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | -$1.63M derived: sum of 2 quarters · filed 2026-06-18 | -$2.48M derived: sum of 3 quarters · filed 2026-06-18 | -$3.20M 10-K · filed 2026-06-18 |
| 2024-12-31 | -$605.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | -$1.46M derived: sum of 2 quarters · filed 2026-02-12 | -$2.18M 10-Q · filed 2026-02-12 | -$3.07M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | -$852.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | -$1.58M 10-Q · filed 2025-11-13 | -$2.47M derived: sum of 3 quarters · filed 2025-11-13 | -$2.67M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$724.00K 10-Q · filed 2025-08-12 | -$1.61M derived: sum of 2 quarters · filed 2025-08-12 | -$1.82M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$891.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | -$1.10M derived: sum of 2 quarters · filed 2025-06-23 | -$1.83M 10-K · filed 2025-06-23 | |
| 2023-12-31 | -$208.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | -$943.00K 10-Q · filed 2025-02-13 | ||
| 2023-09-30 | -$735.00K 10-Q · filed 2024-11-13 | |||
| 2023-03-31 | -$9.54M 10-K · filed 2024-06-21 | |||
| 2022-03-31 | -$648.00K 10-K · filed 2023-06-23 | |||
| 2021-03-31 | $0.00 10-K · filed 2022-06-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |